IAVI and Moderna have initiated human trials of an HIV drug. Prior to this, the mRNA-based tool was tested on macaques.
The messenger RNA (mRNA) used to develop the drug stimulates the body to generate protein bodies that initiate an immune response. Finding a suitable basis for the drug was not easy, but now there is a toolkit that will become key in the production of a highly effective drug.
During the initial phase, the agent will be applied to 56 HIV-negative volunteers. 48 participants will receive 1-2 doses of eOD-GT8 60mer mRNA preparation, followed by Core-g28v2 60mer booster vaccine for 32 participants. The remaining test subjects will cost only a booster.
Further, scientists will follow the experiment for six months. The reaction of the body will be observed at the molecular level.
Experimental drugs for the immunodeficiency virus were created by Scripps Research professor and head of the IAVI Neutralizing Antibody Center's Vaccine Products Division, William Schiff.
Last year, Schif shared information about tests of the drug with the priming immunogen eOD-GT8 60mer with a protein base. That vaccine stimulated a qualitative B-cell response in 97% of recipients. Ongoing trials, however, will monitor the ability of the stimulatory immunogen to induce the subsequent development of B cells.
The messenger RNA (mRNA) used to develop the drug stimulates the body to generate protein bodies that initiate an immune response. Finding a suitable basis for the drug was not easy, but now there is a toolkit that will become key in the production of a highly effective drug.
During the initial phase, the agent will be applied to 56 HIV-negative volunteers. 48 participants will receive 1-2 doses of eOD-GT8 60mer mRNA preparation, followed by Core-g28v2 60mer booster vaccine for 32 participants. The remaining test subjects will cost only a booster.
Further, scientists will follow the experiment for six months. The reaction of the body will be observed at the molecular level.
Experimental drugs for the immunodeficiency virus were created by Scripps Research professor and head of the IAVI Neutralizing Antibody Center's Vaccine Products Division, William Schiff.
Last year, Schif shared information about tests of the drug with the priming immunogen eOD-GT8 60mer with a protein base. That vaccine stimulated a qualitative B-cell response in 97% of recipients. Ongoing trials, however, will monitor the ability of the stimulatory immunogen to induce the subsequent development of B cells.
Login or register to post comments
Comments 0